Peptides displayed by HLA for use immunotherapy against different types of cancers
AssigneeImmatics Biotechnologies GmbH
InventorsRicarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Claims20
A peptide consisting of the amino acid sequence VYIASSFKI (SEQ ID NO:
- 3) in the form of a pharmaceutically acceptable salt.
A pegylated peptide consisting of the amino acid sequence of VYIASSFKI (SEQ ID NO:
- 3) or a pharmaceutically acceptable salt thereof modified with PEG.
A peptide consisting of the amino acid sequence VYIASSFKI (SEQ ID NO:
- 3) in the form of a salt.
A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of VYIASSFKI (SEQ ID NO:
- 3), wherein the cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, gastro-esophageal junction cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, urinary bladder carcinoma, and uterine endometrial cancer.
Dependencies are inferred from the claim text.